Revelation Biosciences Stock Price, News & Analysis

Revelation Biosciences Inc. (NASDAQ: REVB) reported its third quarter 2022 financial results, highlighting key corporate developments. The company completed a $5.0 million public offering and licensed innovative IP for REVTx-100 aimed at healthcare-associated infections. Notably, positive preclinical data for REVTx-300 in kidney-related conditions was announced. As of September 30, 2022, cash and cash equivalents rose to $6.2 million from $1.3 million in 2021. However, the company recorded a net loss of $1.2 million for Q3 2022, down from $3.0 million in Q3 2021, indicating improved financial performance.

Revelation Biosciences Inc. (NASDAQ: REVB) announced promising preclinical results for REVTx-300, demonstrating a significant reduction in renal cortical fibrosis in models of acute kidney injury (AKI) and chronic kidney disease (CKD). High-dose treatment achieved a reduction of 29.3% (p < 0.05). The company plans to initiate Phase 1 clinical studies in the first half of 2023 and explore additional models including NASH and myocarditis. The findings suggest potential therapeutic benefits for health conditions associated with inflammation.

Revelation Biosciences Inc. (NASDAQ: REVB) announced an exclusive worldwide license with Vanderbilt University to develop phosphorylated hexaacyl disaccharide (PHAD) aimed at treating and preventing infections. The agreement focuses on combatting infections related to surgery, severe burns, and antibiotic resistance. Relevant data reveals approximately 687,000 cases of acquired infections leading to 72,000 deaths annually. Preclinical studies indicate PHAD could enhance innate immune response, potentially shortening infection duration and severity. Revelation also plans to prosecute additional patent applications for further innovations.

Revelation Biosciences Inc. (NASDAQ: REVB) reported its Q2 2022 financial results and recent advances on August 15, 2022. The company raised $5 million through a public offering and continues to progress with innovative therapies targeting allergies and chronic diseases.

As of June 30, 2022, cash reserves reached $3.5 million, bolstered by financing activities. Despite a net loss of $1.8 million for Q2 2022, improved from $2.5 million in Q2 2021, clinical studies were key contributors to operational expenses. The company expects sufficient funds to sustain operations through June 2023.

Revelation Biosciences Inc. (NASDAQ: REVB) announced the closure of a public offering on July 28, 2022, involving 8,333,334 shares at $0.60 each, raising approximately $5 million. The offering included warrants for an equal number of shares, exercisable at the same price for five years. The funds will support the development of their key therapeutic candidates, including REVTx-99b, REVTx-200, and REVTx-300, alongside general corporate purposes.

Revelation Biosciences Inc. (NASDAQ: REVB) has announced a public offering of 8,333,334 shares of common stock, priced at $0.60 per share, along with warrants to purchase an equal number of shares. The offering aims to raise approximately $5 million before fees, and proceeds will be used for the development of product candidates REVTx-99b, REVTx-200, and REVTx-300, among other corporate purposes. The offering is expected to close on or about July 28, 2022.

Revelation Biosciences Inc. (NASDAQ: REVB) announced topline data from its Phase 1b CLEAR study assessing intranasal REVTx-99b for allergic rhinitis. The primary endpoint regarding safety and tolerability was met; however, exploratory efficacy endpoints were not satisfied, showing no significant improvement in allergy symptoms or nasal airflow. The study involved two cohorts and took place in Australia. Management is considering future development for REVTx-99b along with other ongoing programs.

Revelation Biosciences Inc. (NASDAQ: REVB) has announced the completion of database lock for its Phase 1b CLEAR clinical study evaluating REVTx-99b for treating allergic rhinitis caused by rye grass pollen. The study, conducted in Australia, aims to assess safety and tolerability against a placebo.

Topline data is expected to be released in the last week of July 2022. This milestone is crucial for developing effective treatments for allergic rhinitis, a condition affecting millions, and could lead to significant advancements in patient care.

Revelation Biosciences (NASDAQ: REVB) has completed the enrollment and dosing of its Phase 1b CLEAR clinical study for REVTx-99b, aimed at treating allergic rhinitis. The study, conducted in Australia, evaluates the safety and efficacy of this intranasal formulation against a placebo. Participants were divided into two cohorts to assess the drug's effects before and after nasal allergen challenges. Topline results are anticipated in Q3 2022, marking a significant step in developing therapies for this prevalent condition.